P/E ratio for iRadimed (IRMD)
P/E ratio as of May 2024 (TTM): 37.8
According to iRadimed's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 37.8017. At the end of 2022 the company had a P/E ratio of 27.7.
P/E ratio history for iRadimed from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 27.7 | -54.98% |
| 2021 | 61.6 | -67.57% |
| 2020 | 190 | 598.89% |
| 2019 | 27.2 | -34.42% |
| 2018 | 41.5 | -86.32% |
| 2017 | 303 | 1756.22% |
| 2016 | 16.3 | -59.82% |
| 2015 | 40.6 | -37.63% |
| 2014 | 65.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Edwards Lifesciences EW | 36.2 | -4.25% | 🇺🇸 USA |
 NuVasive NUVA | 73.6 | 94.73% | 🇺🇸 USA |
 DexCom DXCM | 129 | 241.88% | 🇺🇸 USA |
 AtriCure ATRC | -41.1 | -208.85% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.